Integrating BCMA-directed bispecific antibodies into the treatment paradigm for MM

During the Multiple Myeloma Hub Steering Committee Meeting on May 12, 2026, key opinion leaders met to discuss the integration of B-cell maturation antigen (BCMA)-directed bispecific antibodies (BsAbs) into the treatment paradigm for multiple myeloma. The discussion was led by Miles Prince (Peter MacCallum Cancer Centre, Melbourne, AU) and explored key considerations for patient selection, treatment sequencing, and implementation of BsAb therapy in clinical practice. Prince reviews the currently approved BCMA-directed BsAbs and key factors influencing treatment selection, including disease burden, prior therapy, T-cell fitness, patient preferences, and treatment access. Prince also discusses emerging treatment strategies, including combination regimens and earlier-line use of BsAbs, before exploring practical considerations related to dosing, toxicity management, and community-based treatment delivery. The subsequent discussion focuses on expanding access to BsAb therapy, the role of standardized toxicity management pathways, and challenges associated with transitioning patients from specialist centers to community care. This educational resource is independently supported by Pfizer. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence. Hosted on Acast. See acast.com/privacy for more information.